LabGenomics Co., Ltd.

Equities

A084650

KR7084650001

Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-21 pm EDT			5-day change	1st Jan Change
2,720 ^KRW	+3.62%		+5.02%	-29.44%

2023	LabGenomics USA LLC announced that it has received KRW 75.948 billion in funding from LabGenomics Co., Ltd.	CI
2023	LabGenomics USA LLC announced that it expects to receive KRW 70 billion in funding from LabGenomics Co., Ltd.	CI

Tranche Update on LabGenomics Co., Ltd.'s Equity Buyback Plan announced on May 28, 2021.

August 04, 2021 at 03:30 am EDT

From May 28, 2021 to June 30, 2021, the company has repurchased 38,678 shares, representing 0.34% for KRW 950.95 million. With this, the company has completed the repurchase of 38,678 shares, representing 0.34% for KRW 950.95 million under the buyback announced on May 28, 2021.

Latest news about LabGenomics Co., Ltd.

LabGenomics USA LLC announced that it has received KRW 75.948 billion in funding from LabGenomics Co., Ltd.	23-07-23	CI
LabGenomics USA LLC announced that it expects to receive KRW 70 billion in funding from LabGenomics Co., Ltd.	23-07-02	CI
Abion Inc. announced that it expects to receive KRW 21 billion in funding from LabGenomics Co., Ltd., Atinum Investment Co., Ltd, NH Investment & Securities Co., Ltd., Investment and others	23-04-10	CI
N Citron, Inc. announced that it has received KRW 1.999999776 billion in funding from LabGenomics Co., Ltd.	23-04-09	CI
N Citron, Inc. announced that it expects to receive KRW 1.999999776 billion in funding from LabGenomics Co., Ltd.	23-03-30	CI
LabGenomics Co., Ltd. announced that it has received KRW 22.71198072 billion in funding	23-01-17	CI
LabGenomics Co., Ltd. announced that it expects to receive KRW 34.09367874 billion in funding	22-08-19	CI
LabGenomics Co., Ltd. announced that it expects to receive KRW 82.71198072 billion in funding from Luha Private Equity and another investor	22-08-18	CI
LabGenomics Co., Ltd.'s Equity Buyback announced on May 28, 2021, has expired.	21-08-27	CI
Tranche Update on LabGenomics Co., Ltd.'s Equity Buyback Plan announced on May 28, 2021.	21-08-04	CI
LabGenomics Co., Ltd. announces an Equity Buyback for 214,132 shares.	21-05-27	CI
LabGenomics Co., Ltd. authorizes a Buyback Plan.	21-05-27	CI
Optical Biosystems, Inc. announced that it has received $20 million in funding from a group of investors	20-11-18	CI
LabGenomics Co., Ltd.(KOSDAQ:A084650) added to S&P Global BMI Index	20-09-21	CI
LabGenomics Co., Ltd. agreed to acquire 9.09% stake in Calth Corporation for KRW 2 billion.	20-05-31	CI
Contextual Genomics Partners with Lab Genomics	20-01-20	CI
LabGenomics Co., Ltd's Equity Buyback announced on July 30, 2019, has expired.	19-08-29	CI
LabGenomics Co., Ltd. announces an Equity Buyback for 101,419 shares.	19-07-29	CI
LabGenomics Co., Ltd. authorizes a Buyback Plan.	19-07-29	CI
LabGenomics Co., Ltd. announced that it has received KRW 7 billion in funding from With Investment Co., Ltd. and other investors	18-07-10	CI
LabGenomics Co., Ltd. announced that it expects to receive KRW 7 billion in funding from With Investment Co., Ltd. and other investors	18-07-02	CI
LabGenomics Co., Ltd.(KOSDAQ:A084650) dropped from S&P Global BMI Index	17-09-18	CI
CSquared Global Asset Management acquired 5.63% stake in LabGenomics Co., Ltd..	17-01-04	CI
B-bros announced that it has received KRW 1 billion in funding from LabGenomics Co., Ltd.	16-12-15	CI
LabGenomics Co., Ltd. announced that it has received KRW 10 billion in funding from Moorim Capital Co., Ltd.	16-12-01	CI

Chart LabGenomics Co., Ltd.

Duration

Period

More charts

Company Profile

LabGenomics Co., Ltd is a Korea-based company engaged in the provision of in vitro diagnostic (IVD) services. The Company mainly provides IVD services, including general diagnostic check services, molecular diagnostic check services, and research and development services. The Companyâs IVD products include deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) kits and others. It also provides examination for breast cancer and colorectal cancer, biosensor for point of care testing (POCT) and others. It also provides healthy food.

Sector

Healthcare Facilities & Services

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LabGenomics Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
LABGENOMICS CO., LTD.	-29.44%	146M
SONIC HEALTHCARE LIMITED	-16.30%	8.18B
RADNET, INC.	+37.04%	3.51B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-28.32%	2.9B
SYNLAB AG	-8.06%	2.47B
DR. LAL PATHLABS LIMITED	-12.58%	2.25B
NEOGENOMICS, INC.	-17.06%	1.71B
FLEURY S.A.	-22.34%	1.47B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-39.86%	1.22B
ADICON HOLDINGS LIMITED	-13.80%	1.09B

Medical & Diagnostic Laboratories